OncoMatch/Clinical Trials/NCT06392477
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
Is NCT06392477 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SAR448501 for b-cell non hodgkin lymphoma.
Treatment: SAR448501 — This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL). The purpose of the study is to identify possible optimal biological dosage(s) by assessing safety, tolerability, pharmacokinetics (PK), pharmacodynamics, clinical activity and immunogenicity of SAR448501/DR-0201. The study duration per participant will be approximately 3 years, including a screening period of up to 28 days, a treatment period of 52 weeks, a safety follow-up period of approximately 28 days and a long-term follow-up period of every 3 months until withdrawal of consent, participant death or study closure, whichever is sooner.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic stem cell transplantation
Exception: Follicular lymphoma (FL) and mantle cell lymphoma (MCL) excluded if transplant <100 days prior to dosing or if grade >1 graft versus host disease
Prior allogeneic stem cell transplantation except for those with follicular lymphoma (FL) and mantle cell lymphoma (MCL), who are excluded if transplant occurred less than 100 days prior to dosing or if they exhibit grade > 1 graft versus host disease.
Cannot have received: autologous stem cell transplantation
Exception: Allowed if >100 days prior to dosing
Autologous stem cell transplantation 100 days prior to dosing.
Cannot have received: solid organ transplantation
Prior solid organ transplantation.
Lab requirements
Blood counts
adequate marrow reserve
Kidney function
adequate renal function
Liver function
adequate hepatic function
Adequate marrow reserve, renal function, and hepatic function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06392477 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplantation, autologous stem cell transplantation, solid organ transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages